Chief Accounting Officer
Adaptive Biotechnologies Corp (ADPT)Equibles does not estimate personal net worth.
Get an email with a short summary when Adaptive Biotechnologies Corp publishes a filing, an earnings call transcript or a press release.
Get ADPT alertsKyle Piskel is recorded as Chief Accounting Officer at Adaptive Biotechnologies Corp (ADPT) since October 28, 2021 and CFO at Adaptive Biotechnologies Corp (ADPT). The newest filing on record that lists Kyle Piskel as CFO at Adaptive Biotechnologies Corp (ADPT) is dated April 24, 2026. Adaptive Biotechnologies Corp reported in an 8-K filed April 9, 2024 that Kyle Piskel was appointed Chief Financial Officer, effective April 8, 2024. Adaptive Biotechnologies Corp reported in an 8-K filed April 2, 2024 that Kyle Piskel was appointed Chief Financial Officer, effective April 8, 2024. The proxy statement of Adaptive Biotechnologies Corp reports total compensation of $3,310,729 for Kyle Piskel in fiscal 2025, including a base salary of $399,950. Disclosed compensation is on record for 4 fiscal years. Kyle Piskel has spoken on 13 earnings calls across 1 company, most recently for Adaptive Biotechnologies Corp on November 4, 2026. Adaptive Biotechnologies Corp is classified in the Diagnostics & Research industry within the Healthcare sector. Other leadership on record at Adaptive Biotechnologies Corp includes Chad Robins (CEO and Board Member), Julie Rubinstein (COO), Stacy Taylor (General Counsel) and 3 others.
“As previously announced, Adaptive Biotechnologies Corporation (the “Company”) appointed Kyle Piskel, the Company’s Principal Accounting Officer, to serve as its Chief Financial Officer effective April 8, 2024.”
“Kyle Piskel, who has been with Company for 8 years and is currently its Principal Accounting Officer will serve as the Chief Financial Officer starting on April 8, 2024.”
“I'll start on slide eight with our third quarter results. As a reminder, amortization of Genentech payments within immune medicine is excluded from all prior period comparisons.”
“I'll start on slide 10 with our second quarter results. Total revenue was $71.6 million, an increase of 30% from the prior year, driven by continued strength in MRD, which represented 92% of total company revenue.”
“Starting on slide eight with our first quarter results, total revenue was $70.9 million, representing 45% growth year-over-year, driven primarily by continued strength in MRD, which accounted for approximately 95% of total revenue.”
“First, I'll cover our reported results, which include the non-cash revenue recognized from the Amort of amounts previously received under our Genentech collaboration.”
“First, I will go over the financial results, including $33.7 million of noncash revenue recognized this quarter from the remaining amortization of payments previously received from Genentech.”
2021-10-28–present
Start not stated–present
Last confirmed April 24, 2026
Diagnostics & Research · Healthcare
CFO, Chief Accounting Officer
2021-10-28–present
Compensation components disclosed in company proxy statements. Amounts are nominal USD; total is the company-reported figure.
| Fiscal year | Company | Role | Salary | Total |
|---|---|---|---|---|
| 2025 | Adaptive Biotechnologies Corp (ADPT) | Chief Financial Officer | $399,950 | $3,310,729 |
| 2024 | Adaptive Biotechnologies Corp (ADPT) | Chief Financial Officer | $361,167 | $1,290,346 |
| 2023 | Adaptive Biotechnologies Corp (ADPT) | Chief Financial Officer | $305,295 | $744,046 |
| 2022 | Adaptive Biotechnologies Corp (ADPT) | Chief Financial Officer | $293,550 | $1,659,147 |
